Shorter hemodialysis duration is a risk factor for the recurrence of urothelial carcinoma of the bladder in patients on maintenance hemodialysis

Liu, S.-L.; Qi, Lin; Wang, Han; Zhu, Bisong; Zhou, Xinming; Jiang, Sanyuan; Chen, M.-F.; Li, Y.; He, Wei; Liu, L.-F.; Hu, Xiheng; Xie, Yu; Zeng, Fuhua; Zu, Xiongbing

doi:10.1007/s12094-015-1368-x

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of bladder cancer has gradually increased in recent years. There is a modestly effective clinical prognosis despite systemic therapy for bladder cancer that is characterised by progression, metastasis, recurrence and drug resistance [ 2 , 3 ]. Although a great deal of advanced research has contributed to the understanding of bladder cancer, molecular mechanisms involved in the pathogenesis and progression of this disease remain poorly understood [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells

Zhu

Chen

et al. 2018

Cancer Cell Int

View full text Add to dashboard Cite

BackgroundThe abnormal expression of non-coding RNAs (ncRNAs), such as microRNAs and long ncRNAs, often contribute to the development of cancers. miR-200c functions as a tumour suppressor that impacts the growth of bladder cancer cells and the epithelial-to-mesenchymal transition (EMT). LncRNA X inactive specific transcript (XIST) is highly expressed in tumour tissues, promotes cancer progression and might act as an miRNA molecular sponge. This study aimed to examine the relationship between lncRNA XIST and miR-200c and to assess their functions in the regulation of the stemness properties and tumourigenicity of human bladder cancer stem cell (BCSC)-like cells.MethodsBiological effects including cell clone formation, sphere formation, self-renewal properties and mouse tumourigenesis were examined in BCSC-like cells with miR-200c overexpression or XIST knockdown. Real-time PCR and western blotting were used to detect the expression changing of related factors in BCSC-like cells gene models. Dual luciferase reporter assay was used to examine the changes of XIST and miR-200c expression levels.ResultsThe results indicated that miR-200c overexpression and XIST knockdown could inhibit cell clone formation, self-renewal ability and EMT in BCSC-like cells. miR-200c knockdown could restore the tumour growth inhibition caused by XIST knockdown.ConclusionLncRNA XIST may act as an inhibitor of miR-200c to regulate the stemness properties and tumourigenicity of bladder cancer cells, and our findings might reveal a potential strategy of targeting XIST for bladder cancer therapy.Electronic supplementary materialThe online version of this article (10.1186/s12935-018-0540-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells

Zhu

Chen

et al. 2018

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Moreover, the risk is considered to be progressively higher in patients with a longer duration of dialysis [4]. However, Liu et al [5] showed that the highest standardized incidence ratio of urothelial carcinoma of the bladder occurred in the first 3 years of hemodialysis and that the risk gradually declined with prolonged hemodialysis. Moreover, Ricci [6] reported a significantly lower incidence of metastases in patients on hemodialysis compared with those not on hemodialysis.…”

Section: Discussionmentioning

confidence: 99%

Rapid progression of solitary fibrous tumor after induction of hemodialysis

Yasukawa

Ohbayashi

Uchiyama

et al. 2017

Oxford Medical Case Reports

View full text Add to dashboard Cite

A 42-year-old male patient presented in 2002 with a solitary fibrous tumor (SFT) arising from the visceral pleura of the right lung. Thoracic surgery was performed to remove the tumor. A second operation to remove a recurrent tumor on the parietal pleura of the right thorax was performed in 2010. A follow-up computed tomography (CT) scan revealed local recurrence in the chest wall. And then a third operation involving en bloc resection of chest wall was performed in 2012. Thereafter, a CT scan in 2015 revealed slow-growing local recurrence. In 2016, he was started on hemodialysis. Two months later he was hospitalized because of chest pain and dyspnea. Imaging showed bilateral massive pleural effusion and dissemination along with left pulmonary metastasis. We report a case of SFT recurrence, which rapidly worsened after induction of hemodialysis. Induction of hemodialysis is potentially challenging that may lead to be in a tumor-bearing condition.

show abstract

“…The study protocol was approved by the Medical Research Ethics Committee of the Beijing Manuscript to be reviewed were obtained from all participants. A total of 111 right-handed participants (age ≥ 18 years) were enrolled in this study, including patients with hemodialysis for at least six months (Liu et al 2016b;Yen et al 2009)…”

Section: Participantsmentioning

confidence: 99%

Peer Review #1 of "Disturbed neurovascular coupling in hemodialysis patients (v0.1)"

Zhu¹

2020

View full text Add to dashboard Cite

Background. Altered cerebral blood flow (CBF) and amplitude of low-frequency fluctuation (ALFF) have been reported in hemodialysis patients. However, neurovascular coupling impairments, which provide a novel insight into the human brain, have not been reported in hemodialysis patients. Methods. We combined arterial spin labeling (ASL) and blood oxygen level dependent (BOLD) techniques to investigate neurovascular coupling alterations and its relationships with demographic and clinical data in 46 hemodialysis patients and 47 healthy controls. To explore regional neuronal activity, ALFF was obtained from resting-state functional MRI. To measure cerebral vascular response, CBF was calculated from ASL. The across-voxel CBF-ALFF correlations for global neurovascular coupling and CBF/ALFF ratio for regional neurovascular coupling were compared between hemodialysis patients and healthy controls. Two-sample t-tests were used to compare the intergroup differences in CBF and ALFF. Multiple comparisons were corrected using a voxel-wise false discovery rate (FDR) method (P < 0.05). Results. All hemodialysis patients and healthy controls showed significant across-voxel correlations between CBF and ALFF. Hemodialysis patients showed a significantly reduced global CBF-ALFF coupling (P = 0.0011) compared to healthy controls at the voxel-level. Of note, decreased CBF/ALFF ratio was exclusively located in the bilateral amygdala involved in emotional regulation and cognitive processing in hemodialysis patients. In hemodialysis patients, the decreased CBF (right olfactory cortex, anterior cingulate gyrus and bilateral insula) and ALFF (bilateral precuneus and superior frontal gyrus) were mainly located in the default mode network (DMN) and salience network-related regions as well as increased CBF in the bilateral thalamus. Conclusions. These novel findings reveal that disrupted neurovascular coupling may be a potential neural mechanism in hemodialysis patients.

show abstract

Shorter hemodialysis duration is a risk factor for the recurrence of urothelial carcinoma of the bladder in patients on maintenance hemodialysis

Abstract: Preoperative shorter hemodialysis duration is a risk factor for the occurrence and recurrence of UC of the bladder in patients undergoing MHD.

Cited by 6 publications

References 22 publications

LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells

LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells

Rapid progression of solitary fibrous tumor after induction of hemodialysis

Peer Review #1 of "Disturbed neurovascular coupling in hemodialysis patients (v0.1)"

Contact Info

Product

Resources

About